-
1
-
-
0015171224
-
Estrogen receptors and breast cancer response to adrenalectomy
-
Jensen EV, Block GE, Smith S, Kyser K, DeSomlore ER (1971) Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr 34:55-70
-
(1971)
Natl Cancer Inst Monogr
, vol.34
, pp. 55-70
-
-
Jensen, E.V.1
Block, G.E.2
Smith, S.3
Kyser, K.4
Desomlore, E.R.5
-
2
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182 (Pubitemid 17231334)
-
(1987)
Science
, vol.235
, Issue.4785
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
-
3
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
-
DOI 10.1056/NEJMoa052122
-
Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684 (Pubitemid 41464706)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.16
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
Suman, V.J.4
Geyer Jr., C.E.5
Davidson, N.E.6
Tan-Chiu, E.7
Martino, S.8
Paik, S.9
Kaufman, P.A.10
Swain, S.M.11
Pisansky, T.M.12
Fehrenbacher, L.13
Kutteh, L.A.14
Vogel, V.G.15
Visscher, D.W.16
Yothers, G.17
Jenkins, R.B.18
Brown, A.M.19
Dakhil, S.R.20
Mamounas, E.P.21
Lingle, W.L.22
Klein, P.M.23
Ingle, J.N.24
Wolmark, N.25
more..
-
4
-
-
26844503270
-
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
-
DOI 10.1056/NEJMoa052306
-
Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672 (Pubitemid 41464705)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.16
, pp. 1659-1672
-
-
Piccart-Gebhart, M.J.1
Procter, M.2
Leyland-Jones, B.3
Goldhirsch, A.4
Untch, M.5
Smith, I.6
Gianni, L.7
Baselga, J.8
Bell, R.9
Jackisch, C.10
Cameron, D.11
Dowsett, M.12
Barrios, C.H.13
Steger, G.14
Huang, C.-S.15
Andersson, M.16
Inbar, M.17
Lichinitser, M.18
Lang, I.19
Nitz, U.20
Iwata, H.21
Thomssen, C.22
Lohrisch, C.23
Suter, T.M.24
Ruschoff, J.25
Suto, T.26
Greatorex, V.27
Ward, C.28
Straehle, C.29
McFadden, E.30
Dolci, M.S.31
Gelber, R.D.32
more..
-
5
-
-
4644289313
-
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
-
DOI 10.1158/0008-5472.CAN-04-1168
-
Wood ER, Truesdale AT, McDonald OB et al (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64:6652-6659 (Pubitemid 39297926)
-
(2004)
Cancer Research
, vol.64
, Issue.18
, pp. 6652-6659
-
-
Wood, E.R.1
Truesdale, A.T.2
McDonald, O.B.3
Yuan, D.4
Hassell, A.5
Dickerson, S.H.6
Ellis, B.7
Pennisi, C.8
Horne, E.9
Lackey, K.10
Alligood, K.J.11
Rusnak, D.W.12
Gilmer, T.M.13
Shewchuk, L.14
-
6
-
-
1242273590
-
ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016
-
DOI 10.1038/sj.onc.1207166
-
Xia W, Liu L-H, Ho P, Spector NL (2004) Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW72016. Oncogene 23: 646-653 (Pubitemid 38241266)
-
(2004)
Oncogene
, vol.23
, Issue.3
, pp. 646-653
-
-
Xia, W.1
Liu, L.-H.2
Ho, P.3
Spector, N.L.4
-
7
-
-
33845886440
-
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
-
DOI 10.1056/NEJMoa064320
-
Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743 (Pubitemid 46021510)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.26
, pp. 2733-2743
-
-
Geyer, C.E.1
Forster, J.2
Lindquist, D.3
Chan, S.4
Romieu, C.G.5
Pienkowski, T.6
Jagiello-Gruszfeld, A.7
Crown, J.8
Chan, A.9
Kaufman, B.10
Skarlos, D.11
Campone, M.12
Davidson, N.13
Berger, M.14
Oliva, C.15
Rubin, S.D.16
Stein, S.17
Cameron, D.18
-
8
-
-
0034644539
-
Cell signaling by receptor tyrosine kinases
-
Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103:211-225
-
(2000)
Cell
, vol.103
, pp. 211-225
-
-
Schlessinger, J.1
-
9
-
-
0037291226
-
The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors
-
DOI 10.1016/S1097-2765(03)00048-0
-
Garrett TP, McKern NM, Lou M et al (2003) The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation poised to interact with other ErbB receptors. Mol Cell 11:495-505 (Pubitemid 36293841)
-
(2003)
Molecular Cell
, vol.11
, Issue.2
, pp. 495-505
-
-
Garrett, T.P.J.1
McKern, N.M.2
Lou, M.3
Elleman, T.C.4
Adams, T.E.5
Lovrecz, G.O.6
Kofler, M.7
Jorissen, R.N.8
Nice, E.C.9
Burgess, A.W.10
Ward, C.W.11
-
10
-
-
0033542381
-
Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation
-
DOI 10.1038/sj.onc.1202698
-
Jones FE, Stern DF (1999) Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation. Oncogene 18: 3481-3490 (Pubitemid 29317343)
-
(1999)
Oncogene
, vol.18
, Issue.23
, pp. 3481-3490
-
-
Jones, F.E.1
Stern, D.F.2
-
11
-
-
0033523775
-
ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation
-
DOI 10.1083/jcb.147.1.77
-
Jones FE, Welte T, Fu XY, Stern DF (1999) ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J Cell Biol 147:77-87 (Pubitemid 30211798)
-
(1999)
Journal of Cell Biology
, vol.147
, Issue.1
, pp. 77-87
-
-
Jones, F.E.1
Welte, T.2
Fu, X.-Y.3
Stern, D.F.4
-
12
-
-
0026443334
-
Epidermal growth factor receptor and other oncogenes as prognostic markers
-
Harris AL, Nicholson S, Sainsbury R, Wright C, Farndon J (1992) Epidermal growth factor receptor and other oncogenes as prognostic markers. Natl Cancer Inst Monogr 11:181-187
-
(1992)
Natl Cancer Inst Monogr
, vol.11
, pp. 181-187
-
-
Harris, A.L.1
Nicholson, S.2
Sainsbury, R.3
Wright, C.4
Farndon, J.5
-
13
-
-
0031730476
-
Expression of c-erbB3 protein in primary breast carcinomas
-
Naidu R, Yadav M, Nair S, Kutty MK (1998) Expression of cerbB3 protein in primary breast carcinomas. Br J Cancer 78: 1385-1390 (Pubitemid 28495255)
-
(1998)
British Journal of Cancer
, vol.78
, Issue.10
, pp. 1385-1390
-
-
Naidu, R.1
Yadav, M.2
Nair, S.3
Kutty, M.K.4
-
14
-
-
0024355092
-
Autocrine interaction between TGF and the EGF-receptor: Quantitative requirements for induction of the malignant phenotype
-
Di Marco E, Pierce JH, Fleming TP et al (1989) Autocrine interaction between TGF alpha and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene 4:831-838 (Pubitemid 19176969)
-
(1989)
Oncogene
, vol.4
, Issue.7
, pp. 831-838
-
-
Di Marco, E.1
Pierce, J.H.2
Fleming, T.P.3
Kraus, M.H.4
Molloy, C.J.5
Aaronson, S.A.6
Di Fiore, P.P.7
-
15
-
-
0029665946
-
C-erbB3 in human breast carcinoma: Expression and relation to prognosis and established prognostic indicators
-
Travis A, Pinder SE, Robertson JF et al (1996) C-erbB3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer 74:229-233
-
(1996)
Br J Cancer
, vol.74
, pp. 229-233
-
-
Travis, A.1
Pinder, S.E.2
Robertson, J.F.3
-
16
-
-
0027517374
-
Clinical significance of HER-2/neu oncogene amplification in primary breast cancer
-
Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P (1993) Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11:1936-1942 (Pubitemid 23304619)
-
(1993)
Journal of Clinical Oncology
, vol.11
, Issue.10
, pp. 1936-1942
-
-
Seshadri, R.1
Firgaira, F.A.2
Horsfall, D.J.3
McCaul, K.4
Setlur, V.5
Kitchen, P.6
-
17
-
-
0036467826
-
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
-
DOI 10.1200/JCO.20.3.719
-
Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726 (Pubitemid 34111379)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.3
, pp. 719-726
-
-
Vogel, C.L.1
Cobleigh, M.A.2
Tripathy, D.3
Gutheil, J.C.4
Harris, L.N.5
Fehrenbacher, L.6
Slamon, D.J.7
Murphy, M.8
Novotny, W.F.9
Burchmore, M.10
Shak, S.11
Stewart, S.J.12
Press, M.13
-
18
-
-
0032850677
-
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
-
Cobleigh MA, Vogel CL, Tripathy D et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648 (Pubitemid 29415219)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.9
, pp. 2639-2648
-
-
Cobleigh, M.A.1
Vogel, C.L.2
Tripathy, D.3
Robert, N.J.4
Scholl, S.5
Fehrenbacher, L.6
Wolter, J.M.7
Paton, V.8
Shak, S.9
Lieberman, G.10
Slamon, D.J.11
-
19
-
-
0036534121
-
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer
-
DOI 10.1200/JCO.2002.07.058
-
Esteva FJ, Valero V, Booser D et al (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800-1808 (Pubitemid 34273269)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.7
, pp. 1800-1808
-
-
Esteva, F.J.1
Valero, V.2
Booser, D.3
Guerra, L.T.4
Murray, J.L.5
Pusztai, L.6
Cristofanilli, M.7
Arun, B.8
Esmaeli, B.9
Fritsche, H.A.10
Sneige, N.11
Smith, T.L.12
Hortobagyi, G.N.13
-
20
-
-
0041885349
-
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm
-
DOI 10.1200/JCO.2003.02.018
-
Burstein HJ, Harris LN, Marcom PK et al (2003) Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21: 2889-2895 (Pubitemid 46621838)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.15
, pp. 2889-2895
-
-
Burstein, H.J.1
Harris, L.N.2
Marcom, P.K.3
Lambert-Falls, R.4
Havlin, K.5
Overmoyer, B.6
Friedlander Jr., R.J.7
Gargiulo, J.8
Strenger, R.9
Vogel, C.L.10
Ryan, P.D.11
Ellis, M.J.12
Nunes, R.A.13
Bunnell, C.A.14
Campos, S.M.15
Hallor, M.16
Gelman, R.17
Winer, E.P.18
-
21
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2
-
DOI 10.1056/NEJM200103153441101
-
Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792 (Pubitemid 32222155)
-
(2001)
New England Journal of Medicine
, vol.344
, Issue.11
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
Fleming, T.7
Eiermann, W.8
Wolter, J.9
Pegram, M.10
Baselga, J.11
Norton, L.12
-
22
-
-
23944476155
-
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
-
DOI 10.1200/JCO.2005.16.584
-
Burris HA III, Hurwitz HI, Dees EC et al (2005) Phase I study, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23:5305-5313 (Pubitemid 46206984)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.23
, pp. 5305-5313
-
-
Burris III, H.A.1
Hurwitz, H.I.2
Dees, E.C.3
Dowlati, A.4
Blackwell, K.L.5
O'Neil, B.6
Marcom, P.K.7
Ellis, M.J.8
Overmoyer, B.9
Jones, S.F.10
Harris, J.L.11
Smith, D.A.12
Koch, K.M.13
Stead, A.14
Mangum, S.15
Spector, N.L.16
-
23
-
-
20844437246
-
Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects
-
DOI 10.1023/B:DRUG.0000047104.45929.ea
-
Bence AK, Anderson EB, Halepota MA et al (2005) Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs 23:39-49 (Pubitemid 39505950)
-
(2005)
Investigational New Drugs
, vol.23
, Issue.1
, pp. 39-49
-
-
Bence, A.K.1
Anderson, E.B.2
Halepota, M.A.3
Doukas, M.A.4
DeSimone, P.A.5
Davis, G.A.6
Smith, D.A.7
Koch, K.M.8
Stead, A.G.9
Mangum, S.10
Bowen, C.J.11
Spector, N.L.12
Hsieh, S.13
Adams, V.R.14
-
24
-
-
2942592008
-
Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ErbB-2 inhibitor lapatinib
-
Burris HA III (2004) Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 9(suppl 3):10-15
-
(2004)
Oncologist
, vol.9
, Issue.SUPPL. 3
, pp. 10-15
-
-
Burris Iii, H.A.1
-
25
-
-
0029912203
-
All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired
-
DOI 10.1074/jbc.271.9.5251
-
Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G (1996) All erbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 271: 5251-5257 (Pubitemid 26075021)
-
(1996)
Journal of Biological Chemistry
, vol.271
, Issue.9
, pp. 5251-5257
-
-
Baulida, J.1
Kraus, M.H.2
Alimandi, M.3
Di Fiore, P.P.4
Carpenter, G.5
-
26
-
-
0032526729
-
Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers
-
DOI 10.1093/emboj/17.12.3385
-
Lenferink AEG, Pinkas-Kramarski R, van de Poll MLM et al (1998) Differential endocytic routing of homo- and heterodimeric erbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 17:3385-3397 (Pubitemid 28279512)
-
(1998)
EMBO Journal
, vol.17
, Issue.12
, pp. 3385-3397
-
-
Lenferink, A.E.G.1
Pinkas-Kramarski, R.2
Van De Poll, M.L.M.3
Van Vugt, M.J.H.4
Klapper, L.N.5
Tzahar, E.6
Waterman, H.7
Sela, M.8
Van Zoelen, E.J.J.9
Yarden, Y.10
-
27
-
-
34948909630
-
Lapatinib (L) plus capecitabine (C) in HER2+advanced breast cancer (ABC): Genomic and updated efficacy data
-
abstr 1035
-
Geyer CE, Martin A, Newstat B et al (2007) Lapatinib (L) plus capecitabine (C) in HER2+advanced breast cancer (ABC): genomic and updated efficacy data. Proc Am Soc Clin Oncol 25(18S), abstr 1035
-
(2007)
Proc Am Soc Clin Oncol
, vol.25
, Issue.18 S
-
-
Geyer, C.E.1
Martin, A.2
Newstat, B.3
-
28
-
-
56549113680
-
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses
-
Jan 11 [Epub ahead of print]
-
Cameron D, Casey M, Press M et al (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat Jan 11 [Epub ahead of print]
-
(2008)
Breast Cancer Res Treat
-
-
Cameron, D.1
Casey, M.2
Press, M.3
-
29
-
-
34047248199
-
Lapatinib plus capecitabine in breast cancer
-
Sonpavde G (2007) Lapatinib plus capecitabine in breast cancer. N Engl J Med 356:1471-1472
-
(2007)
N Engl J Med
, vol.356
, pp. 1471-1472
-
-
Sonpavde, G.1
-
30
-
-
34147096113
-
Lapatinib plus capecitabine in breast cancer
-
Geyer CE, Forster J, Cameron MD (2007) Lapatinib plus capecitabine in breast cancer. N Engl J Med 356:1471-1472
-
(2007)
N Engl J Med
, vol.356
, pp. 1471-1472
-
-
Geyer, C.E.1
Forster, J.2
Cameron, M.D.3
-
31
-
-
30544440228
-
Interim results of a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with FISH-amplified advanced or metastatic breast cancer
-
Stein SH, Gomez HL, Chavez MA et al (2005) Interim results of a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with FISH-amplified advanced or metastatic breast cancer. Eur J Cancer 3(suppl):78
-
(2005)
Eur J Cancer
, vol.3
, Issue.SUPPL.
, pp. 78
-
-
Stein, S.H.1
Gomez, H.L.2
Chavez, M.A.3
-
32
-
-
2942652871
-
Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
-
Shou J, Massarweh S, Osborne CK et al (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu crosstalk in ER/HER0-posivitive breast cancer. J Natl Cancer Inst 96:926-935 (Pubitemid 38868139)
-
(2004)
Journal of the National Cancer Institute
, vol.96
, Issue.12
, pp. 926-935
-
-
Shou, J.1
Massarweh, S.2
Osborne, C.K.3
Wakeling, A.E.4
Ali, S.5
Weiss, H.6
Schiff, R.7
-
33
-
-
34250655315
-
Cardiac safety experience in 3127 patients treated with lapatinib
-
Perez EA, Byrne JA, Hammond IW et al (2006) Cardiac safety experience in 3127 patients treated with lapatinib. Ann Oncol 17(suppl 9):1420
-
(2006)
Ann Oncol
, vol.17
, Issue.SUPPL. 9
, pp. 1420
-
-
Perez, E.A.1
Byrne, J.A.2
Hammond, I.W.3
-
34
-
-
0033838655
-
Incidence and epidemiology of heart failure
-
Kannel WB (2000) Incidence and epidemiology of heart failure. Heart Fail Rev 5:167-173
-
(2000)
Heart Fail Rev
, vol.5
, pp. 167-173
-
-
Kannel, W.B.1
-
35
-
-
33645792831
-
Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy
-
Montemurro F, Donadio M, Clavarezza M et al (2006) Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 11: 318-324
-
(2006)
Oncologist
, vol.11
, pp. 318-324
-
-
Montemurro, F.1
Donadio, M.2
Clavarezza, M.3
-
36
-
-
34948911758
-
Preclinical study of continuous administration trastuzumab as combination therapy after disease progresses with trastuzumab monotherapy
-
abstr 5062
-
Fujimoto-Ouchi K, Sekiguchi F, More I (2005) Preclinical study of continuous administration trastuzumab as combination therapy after disease progresses with trastuzumab monotherapy. Proc Am Assoc Cancer Res 46, abstr 5062
-
(2005)
Proc Am Assoc Cancer Res
, vol.46
-
-
Fujimoto-Ouchi, K.1
Sekiguchi, F.2
More, I.3
-
37
-
-
3242720345
-
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer
-
DOI 10.1056/NEJMoa033025
-
Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 351: 337-345 (Pubitemid 38944402)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.4
, pp. 337-345
-
-
Cunningham, D.1
Humblet, Y.2
Siena, S.3
Khayat, D.4
Bleiberg, H.5
Santoro, A.6
Bets, D.7
Mueser, M.8
Harstrick, A.9
Verslype, C.10
Chau, I.11
Van Cutsem, E.12
-
38
-
-
22344446208
-
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group
-
DOI 10.1200/JCO.2005.04.173
-
Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23:4265-4274 (Pubitemid 46207001)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.19
, pp. 4265-4274
-
-
Marty, M.1
Cognetti, F.2
Maraninchi, D.3
Snyder, R.4
Mauriac, L.5
Tubiana-Hulin, M.6
Chan, S.7
Grimes, D.8
Anton, I.9
Lluch, A.10
Kennedy, J.11
O'Byrne, K.12
Conte, P.13
Green, M.14
Ward, C.15
Mayne, K.16
Extra, J.-M.17
-
39
-
-
33645538673
-
Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study
-
Bartsch R, Wenzel C, Hussian D et al (2006) Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer 6:63-68
-
(2006)
BMC Cancer
, vol.6
, pp. 63-68
-
-
Bartsch, R.1
Wenzel, C.2
Hussian, D.3
-
40
-
-
28344441711
-
Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer
-
Garcia-Saenz JA, Martin M, Puente J et al (2005) Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer 6:325-329 (Pubitemid 41715693)
-
(2005)
Clinical Breast Cancer
, vol.6
, Issue.4
, pp. 325-329
-
-
Garcia-Saenz, J.A.1
Martin, M.2
Puente, J.3
Lopez-Tarruella, S.4
Casado, A.5
Moreno, F.6
Grande, E.7
Diaz-Rubio, E.8
-
41
-
-
3042676349
-
Use of trastuzumab beyond disease progression: Observations from a retrospective review of case histories
-
Gelmon KA, Mackey J, Verma S et al (2004) Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 5:52-58. (Pubitemid 38821191)
-
(2004)
Clinical Breast Cancer
, vol.5
, Issue.1
, pp. 52-58
-
-
Gelmon, K.A.1
Mackey, J.2
Verma, S.3
Gertler, S.Z.4
Bangemann, N.5
Klimo, P.6
Schneeweiss, A.7
Bremer, K.8
Soulieres, D.9
Tonkin, K.10
Bell, R.11
Heinrich, B.12
Grenier, D.13
Dias, R.14
-
42
-
-
12744279331
-
Increased risk of brain metastasis in patients with HER-2/neupositive breast carcinoma
-
Altaha R, Crowell E, Hobbs G, Higa G, Abraham J (2005) Increased risk of brain metastasis in patients with HER-2/neupositive breast carcinoma. Cancer 103:442-443
-
(2005)
Cancer
, vol.103
, pp. 442-443
-
-
Altaha, R.1
Crowell, E.2
Hobbs, G.3
Higa, G.4
Abraham, J.5
-
43
-
-
34948902249
-
Brain metastases (BM) in patients treated with trastuzumab for HER overexpressing metastatic breast cancer (MBC): Incidence and survival
-
abstr 1568
-
Stemmler J, Kahlert S, Siekiera Wet al (2005) Brain metastases (BM) in patients treated with trastuzumab for HER overexpressing metastatic breast cancer (MBC): incidence and survival. J Clin Oncol 23(16 suppl), abstr 1568
-
(2005)
J Clin Oncol
, vol.23
, Issue.16 SUPPL.
-
-
Stemmler, J.1
Kahlert, S.2
Siekiera, W.3
-
44
-
-
33746512271
-
Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer
-
abstr 503
-
Lin NU, Carey LA, Liu MC et al (2006) Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J Clin Oncol 24(18S Part I), abstr 503
-
(2006)
J Clin Oncol
, vol.24
, Issue.18 PART I
-
-
Lin, N.U.1
Carey, L.A.2
Liu, M.C.3
-
45
-
-
34848899905
-
EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT)
-
abstr 1012
-
Lin NU, Dieras V, Paul D et al (2007) EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). Proc Am Soc Clin Oncol 25(18S), abstr 1012
-
(2007)
Proc Am Soc Clin Oncol
, vol.25
, Issue.18 S
-
-
Lin, N.U.1
Dieras, V.2
Paul, D.3
-
46
-
-
0029053716
-
Cooperative signaling of erbB3 and erbB2 in neoplastic transformation and human mammary carcinomas
-
Alimandi M, Romano A, Curia MC et al (1995) Cooperative signaling of erbB3 and erbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10:1813-1821
-
(1995)
Oncogene
, vol.10
, pp. 1813-1821
-
-
Alimandi, M.1
Romano, A.2
Curia, M.C.3
-
47
-
-
0024395587
-
Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts
-
DOI 10.1016/0092-8674(89)90843-X
-
Kokai Y, Myers JN, Wada T et al (1989) Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58:287-292 (Pubitemid 19191411)
-
(1989)
Cell
, vol.58
, Issue.2
, pp. 287-292
-
-
Kokai, Y.1
Myers, J.N.2
Wada, T.3
Brown, V.I.4
LeVea, C.M.5
Davis, J.G.6
Dobashi, K.7
Greene, M.I.8
-
48
-
-
0023733226
-
Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene
-
Segatto O, King CR, Pierce JH, DiFiore PP, Aaronson SA (1988) Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Biol 8:5570-5574
-
(1988)
Mol Cell Biol
, vol.8
, pp. 5570-5574
-
-
Segatto, O.1
King, C.R.2
Pierce, J.H.3
Difiore, P.P.4
Aaronson, S.A.5
-
49
-
-
0034082031
-
Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer
-
Colomer R, Montero S, Lluch A et al (2000) Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 6:2356-2362 (Pubitemid 30399203)
-
(2000)
Clinical Cancer Research
, vol.6
, Issue.6
, pp. 2356-2362
-
-
Colomer, R.1
Montero, S.2
Lluch, A.3
Ojeda, B.4
Barnadas, A.5
Casado, A.6
Massuti, B.7
Cortes-Funes, H.8
Lloveras, B.9
-
50
-
-
0036187710
-
2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer
-
Molina MA, Saez R, Ramsey et al (2002) NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 8:347-353 (Pubitemid 34193949)
-
(2002)
Clinical Cancer Research
, vol.8
, Issue.2
, pp. 347-353
-
-
Molina, M.A.1
Saez, R.2
Ramsey, E.E.3
Garcia-Barchino, M.-J.4
Rojo, F.5
Evans, A.J.6
Albanell, J.7
Keenan, E.J.8
Lluch, A.9
Garcia-Conde, J.10
Baselga, J.11
Clinton, G.M.12
-
51
-
-
0035893560
-
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo
-
Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL (2001) Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61:8887-8895 (Pubitemid 34013905)
-
(2001)
Cancer Research
, vol.61
, Issue.24
, pp. 8887-8895
-
-
Moulder, S.L.1
Yakes, F.M.2
Muthuswamy, S.K.3
Bianco, R.4
Simpson, J.F.5
Arteaga, C.L.6
-
52
-
-
20144377465
-
HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells
-
DOI 10.1158/0008-5472.CAN-04-2748
-
Hirata A, Hosoi F, Miyagawa M et al (2005) HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res 65:4253-4260 (Pubitemid 40775664)
-
(2005)
Cancer Research
, vol.65
, Issue.10
, pp. 4253-4260
-
-
Hirata, A.1
Hosoi, F.2
Miyagawa, M.3
Ueda, S.-I.4
Naito, S.5
Fujii, T.6
Kuwano, M.7
Ono, M.8
-
53
-
-
0037388251
-
ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells
-
Anido J, Matar P, Albanell et al (2003) ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER-overexpressing breast cancer cells. Clin Cancer Res 9: 1274-1283 (Pubitemid 36418377)
-
(2003)
Clinical Cancer Research
, vol.9
, Issue.4
, pp. 1274-1283
-
-
Anido, J.1
Matar, P.2
Albanell, J.3
Guzman, M.4
Rojo, F.5
Arribas, J.6
Averbuch, S.7
Baselga, J.8
-
54
-
-
0031010495
-
Secondary dimerization between members of the epidermal growth factor receptor family
-
DOI 10.1074/jbc.272.18.12052
-
Gamett DC, Pearson G, Cerione RA, Friedberg I (1997) Secondary dimerization between members of the epidermal growth factor receptor family. J Biol Chem 272:12052-12056 (Pubitemid 27202783)
-
(1997)
Journal of Biological Chemistry
, vol.272
, Issue.18
, pp. 12052-12056
-
-
Gamett, D.C.1
Pearson, G.2
Cerione, R.A.3
Friedberg, I.4
-
55
-
-
0028968949
-
Tyrosine kinase inhibition: An approach to drug development
-
Levitzki A, Gazit A (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267:1782-1788
-
(1995)
Science
, vol.267
, pp. 1782-1788
-
-
Levitzki, A.1
Gazit, A.2
-
56
-
-
23944464495
-
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer
-
Baselga J, Albanell J, Ruiz A et al (2005) Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 23:5323-5233
-
(2005)
J Clin Oncol
, vol.23
, pp. 5323-5233
-
-
Baselga, J.1
Albanell, J.2
Ruiz, A.3
-
57
-
-
26844455578
-
Clinical value of epidermal growth factor receptor expression in primary breast cancer
-
Rampaul RS, Pinder SE, Nicholson RI, Gullick WJ, Robertson JF, Ellis IO (2005) Clinical value of epidermal growth factor receptor expression in primary breast cancer. Adv Anat Pathol 12:272-273
-
(2005)
Adv Anat Pathol
, vol.12
, pp. 272-273
-
-
Rampaul, R.S.1
Pinder, S.E.2
Nicholson, R.I.3
Gullick, W.J.4
Robertson, J.F.5
Ellis, I.O.6
-
58
-
-
0036848757
-
Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer
-
Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J, Hachitanda Y (2002) Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res 8:3454-3460 (Pubitemid 35340721)
-
(2002)
Clinical Cancer Research
, vol.8
, Issue.11
, pp. 3454-3460
-
-
Tsutsui, S.1
Kataoka, A.2
Ohno, S.3
Murakami, S.4
Kinoshita, J.5
Hachitanda, Y.6
-
59
-
-
20844456577
-
A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer
-
DOI 10.1007/s10549-004-1720-2
-
von Minckwitz G, Jonat W, Fasching P et al (2005) A multicentre phase II study on geftinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 89: 165-172 (Pubitemid 40249050)
-
(2005)
Breast Cancer Research and Treatment
, vol.89
, Issue.2
, pp. 165-172
-
-
Von Minckwitz, G.1
Jonat, W.2
Fasching, P.3
Du Bois, A.4
Kleeberg, U.5
Luck, H.-J.6
Kettner, E.7
Hilfrich, J.8
Eiermann, W.9
Torode, J.10
Schneeweiss, A.11
-
60
-
-
33749011681
-
A phase I study of cetuximab in combination with paclitaxel in patients with advanced-stage breast cancer
-
Modi S, D'Andrea G, Norton L et al (2006) A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer 7:270-277 (Pubitemid 44445741)
-
(2006)
Clinical Breast Cancer
, vol.7
, Issue.3
, pp. 270-277
-
-
Modi, S.1
D'Andrea, G.2
Norton, L.3
Yao, T.J.4
Caravelli, J.5
Rosen, P.P.6
Hudis, C.7
Seidman, A.D.8
-
61
-
-
33644626501
-
ECOG E1100: A phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2)
-
ECOG E1100: a phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2). Clin Adv Hematol Oncol 2003;1:237
-
(2003)
Clin Adv Hematol Oncol
, vol.1
, pp. 237
-
-
|